182 related articles for article (PubMed ID: 35155195)
21. Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin αvβ3 Receptors in the Treatment of Neuroblastoma.
Karakus OO; Godugu K; Rajabi M; Mousa SA
J Med Chem; 2020 Jul; 63(14):7653-7662. PubMed ID: 32571015
[TBL] [Abstract][Full Text] [Related]
22. Nano-Targeting of Thyrointegrin αvβ3 Receptor in Solid Tumors and Impact on Radiosensitization.
Sudha T; Rehman MU; Darwish NHE; Coskun MD; Satti JA; Davis PJ; Mousa SA
Radiat Res; 2021 Oct; 196(4):375-385. PubMed ID: 34260732
[TBL] [Abstract][Full Text] [Related]
23. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
[TBL] [Abstract][Full Text] [Related]
24. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
25. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
Huang X; Schwind S; Yu B; Santhanam R; Wang H; Hoellerbauer P; Mims A; Klisovic R; Walker AR; Chan KK; Blum W; Perrotti D; Byrd JC; Bloomfield CD; Caligiuri MA; Lee RJ; Garzon R; Muthusamy N; Lee LJ; Marcucci G
Clin Cancer Res; 2013 May; 19(9):2355-67. PubMed ID: 23493348
[TBL] [Abstract][Full Text] [Related]
26. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
[No Abstract] [Full Text] [Related]
27. Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.
Zhou J; Bi C; Ching YQ; Chooi JY; Lu X; Quah JY; Toh SH; Chan ZL; Tan TZ; Chong PS; Chng WJ
J Hematol Oncol; 2017 Jul; 10(1):138. PubMed ID: 28693523
[TBL] [Abstract][Full Text] [Related]
28. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
29. Angiocidin induces differentiation of acute myeloid leukemia cells.
Tuszynski GP; Rothman VL
Exp Mol Pathol; 2013 Dec; 95(3):249-54. PubMed ID: 24036285
[TBL] [Abstract][Full Text] [Related]
30. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease.
Risueño RM; Campbell CJ; Dingwall S; Levadoux-Martin M; Leber B; Xenocostas A; Bhatia M
Blood; 2011 Jun; 117(26):7112-20. PubMed ID: 21562049
[TBL] [Abstract][Full Text] [Related]
31. Correction: Godugu et al. Anti-Cancer Activities of Thyrointegrin α
Godugu K; Rajabi M; Mousa SA
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358892
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models.
Rettinger E; Meyer V; Kreyenberg H; Volk A; Kuçi S; Willasch A; Koscielniak E; Fulda S; Wels WS; Boenig H; Klingebiel T; Bader P
Front Oncol; 2012; 2():32. PubMed ID: 22655268
[TBL] [Abstract][Full Text] [Related]
33. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
[TBL] [Abstract][Full Text] [Related]
34. The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation.
Reikvam H; Hatfield KJ; Fredly H; Nepstad I; Mosevoll KA; Bruserud Ø
Eur Cytokine Netw; 2012; 23(4):140-53. PubMed ID: 23328436
[TBL] [Abstract][Full Text] [Related]
35. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
[TBL] [Abstract][Full Text] [Related]
36. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
37. Treatment of acute myeloid leukemia by directly targeting both leukemia stem cells and oncogenic molecule with specific scFv-immunolipoplexes as a deliverer.
Wang GP; Qi ZH; Chen FP
Med Hypotheses; 2008; 70(1):122-7. PubMed ID: 17566667
[TBL] [Abstract][Full Text] [Related]
38. Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening.
Sharma A; Jyotsana N; Lai CK; Chaturvedi A; Gabdoulline R; Görlich K; Murphy C; Blanchard JE; Ganser A; Brown E; Hassell JA; Humphries RK; Morgan M; Heuser M
Curr Cancer Drug Targets; 2016; 16(9):818-828. PubMed ID: 27321378
[TBL] [Abstract][Full Text] [Related]
39. Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation.
Barth BM; Keasey NR; Wang X; Shanmugavelandy SS; Rampal R; Hricik T; Cabot MC; Kester M; Wang HG; Shultz LD; Tallman MS; Levine RL; Loughran TP; Claxton DF
J Leuk (Los Angel); 2014 Sep; 2(3):. PubMed ID: 28239612
[TBL] [Abstract][Full Text] [Related]
40. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
Kovtun Y; Jones GE; Adams S; Harvey L; Audette CA; Wilhelm A; Bai C; Rui L; Laleau R; Liu F; Ab O; Setiady Y; Yoder NC; Goldmacher VS; Chari RVJ; Pinkas J; Chittenden T
Blood Adv; 2018 Apr; 2(8):848-858. PubMed ID: 29661755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
